| 晚期原发性十二指肠腺癌的诊断和治疗 |
| |
| 引用本文： | 陈莹莹1,' target='_blank'>2,谭煌英2. 晚期原发性十二指肠腺癌的诊断和治疗[J]. 现代肿瘤医学, 2019, 0(16): 2962-2965. DOI: 10.3969/j.issn.1672-4992.2019.16.040 |
| |
| 作者姓名： | 陈莹莹1 ' target='_blank'>2 谭煌英2 |
| |
| 作者单位： | 1.北京中医药大学，北京 100029;2.中日友好医院中西结合肿瘤内科，北京 100029 |
| |
| 基金项目： | National Natural Science Foundation of China(No.81673763);国家自然科学基金资助项目(编号:81673763) |
| |
| 摘 要： | 原发性十二指肠腺癌发病率低，起病很隐匿，临床症状不具典型性，预后不佳，临床上采用内镜加活检、CT等检查方法可提高诊断准确率。早诊断、早治疗对疾病的预后尤其重要，晚期患者多采用全身化疗，XELOX、FOLFOX及FOLFIRI等方案可作为晚期患者的治疗选择。近年来，随着内窥镜技术及影像学技术的进步，原发性十二指肠腺癌检出率逐渐提高，本文就原发性十二指肠腺癌的诊治现状作简要总结。
|
| 关 键 词： | 十二指肠腺癌 晚期 诊断 治疗 |
Diagnosis and treatment of advanced primary duodenal adenocarcinoma |
| |
| Chen Yingying1,' target='_blank'>2,Tan Huangying2. Diagnosis and treatment of advanced primary duodenal adenocarcinoma[J]. Journal of Modern Oncology, 2019, 0(16): 2962-2965. DOI: 10.3969/j.issn.1672-4992.2019.16.040 |
| |
| Authors: | Chen Yingying1 ' target='_blank'>2 Tan Huangying2 |
| |
| Affiliation: | 1.Beijing University of Chinese Medicine，Beijing 100029,China；2.Department of Integrative Oncology,China-Japan Friendship Hospital,Beijing 100029,China. |
| |
| Abstract: | The incidence of primary duodenal adenocarcinoma is low.The onset is concealed.The clinical symptoms are not typical,and the prognosis is poor.Clinically,the use of endoscopic biopsy,CT and other methods can improve the diagnostic accuracy.Early diagnosis and early treatment are especially important for the prognosis of the disease.Systemic chemotherapy is often used in patients with advanced disease.XELOX,FOLFOX and FOLFIRI can be used as treatment options for advanced patients.In recent years,with the advancement of endoscopic techniques and imaging techniques,the detection rate of primary duodenal adenocarcinoma has gradually increased.This article briefly summarizes the diagnosis and treatment of primary duodenal adenocarcinoma. |
| |
| Keywords: | duodenal adenocarcinoma advanced stage diagnosis treatment |
|
| 点击此处可从《现代肿瘤医学》浏览原始摘要信息 |
|
点击此处可从《现代肿瘤医学》下载免费的PDF全文 |
